Spots Global Cancer Trial Database for A Long Term Safety Study With Atrasentan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Long Term Safety Study With Atrasentan
Official Title: A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan
Study ID: NCT00127478
Interventions
Study Description
Brief Summary: The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Prostate Oncology Specialists, Marina Del Rey, California, United States
Western Clinical Research, Inc., Torrance, California, United States
South Florida Medical Research, Aventura, Florida, United States
Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter, New York, New York, United States
ViaHealth Rochester General Hospital Center for Urology, Rochester, New York, United States
Oregon Urology Specialist, Division of Clinical Research, Springfield, Oregon, United States
University of Pittsburgh Department of Urology, Pittsburgh, Pennsylvania, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
CroMedia Prime/Prime Trials Vancouver Hospital, Vancouver, British Columbia, Canada
Ken Janz MD, Burlington, Ontario, Canada
McMaster Institute of Urology, Hamilton, Ontario, Canada
McGill University Health Center Royal VIctoria Hosptial, Montreal, Quebec, Canada
Hoptial de Ranguell Service d'Urologie, Toulouse, Cedex, France
University Hospital Rotterdam, Department of Urology, Rotterdam, , Netherlands
Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept., Crewe, , United Kingdom
Contact Details
Name: Gary Gordon, MD
Affiliation: Abbott
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
